Akademik Veri Yönetim Sistemi
Jinekoloji ve Obstetrik Dergisi, cilt.14, sa.3, ss.155-160, 2000 (Scopus)
OBJECTIVE: The aim of this study was to evaluate cardiovascular protective effects of oral and transdermal hormone replacement therapies on haemostatic risk factors for cardiovascular disease. STUDY DESIGN: This prospective randomized open study included 50 natural or surgical postmenopausal women. Of the 50 patients, 26 received hormone replacement therapy (HRT) consisting of 17-b estradiol and Norethindrone acetate (NETA) orally and 24 transdermally. Fibrinogen, factor VII and AT-III plasma levels were measured prior to therapy and in the third month of HRT and levels were compared statistically. RESULTS: A slightly but not statistically significant decrease of the plasma fibrinogen levels was observed in both oral and transdermal group. Although Factor VII levels decreased in both groups, this was statistically significant only in the transdermal group. In the transdermal group, factor VII level decreased from 0.421±0.14 gr/L to 0.293±8.15 gr/L (p<0.0001). Although a decrease of plasma AT-III levels has been observed also in transdermal group, this was not statistically significant. CONCLUSION: Our results show that during hormone replacement therapy factor VII levels decrease significantly by transdermal administration. However AT-III levels fall significantly by oral administration. Although a decrease of plasma AT-III levels has been observed also in transdermal group, this was not statistically significant. Falling levels of factor VII and fibrinogen, which are the most important two haemostatic cardiovascular risk factors, are supporting the preventative effects of hormone replacement therapy on cardiovascular disease.